Abstract:ID 98732 Poster Board 486 Addiction to tobacco and nicotine products remains a leading cause of disease and death worldwide, and an increasing number of never-smokers are being exposed to nicotine via e-cigarettes. With only a few moderately efficacious smoking-cessation therapeutics available, achieving long-term abstinence from nicotine addiction is an unattainable goal for millions. The role of brain nicotinic acetylcholine receptors (nAChRs) in nicotine's behavioral effects leading to tobacco addiction is well recognized. However, the neurobiological basis underlying the role of specific nAChRs in nicotine's behavioral effects remains poorly understood. Our recently published findings have emphasized the role of the high-sensitivity isoform of the α4β2 nAChRs (the HS (α4)2(β2)3 nAChR) in nicotine-associated behavior. Therefore, our current efforts are focused on the development of novel positive allosteric modulators (PAMs) that selectively target the HS (α4)2(β2)3 nAChR for in vivo applications to probe the function of this major nAChR subtype as well as for potential therapeutic applications as smoke-cessation aid. Unlike classical nAChR agonists, which bind at the evolutionary conserved ACh binding site, PAMs bind to sites that are less conserved and potentially unique to the HS (α4)2(β2)3 nAChR making the subtype selectively more attenable. In addition, PAMs act only in the presence of the endogenous neurotransmitter, minimizing tonic activation, desensitization, receptor upregulation, and alteration in the pattern of cholinergic synaptic transmission seen with nAChR agonists. Using three nAChR PAM pharmacophores and computational ligand docking predictions, we synthesized a series of derivatives and examined their nAChR PAM activities (ability to enhance ACh-induced current responses) in vitro . Candidates with potent and efficacious in vitro HS (α4)2(β2)3 nAChR PAM activities are currently being evaluated for their ability to reduce nicotine self-intake and withdrawal symptoms in mice.

Scaffold Ranking and Positional Scanning Utilized in the Discovery of Nachr-Selective Compounds Suitable for Optimization Studies

Optimizing positive allosteric modulators to selectively target the high sensitivity 23 nicotinic acetylcholine receptor

Highly selective and potent α4β2 nAChR antagonist inhibits nicotine self-administration and reinstatement in rats.

SR9883 is a novel small-molecule enhancer of α4β2* nicotinic acetylcholine receptor signaling that decreases intravenous nicotine self-administration in rats

From Α4β2 Nicotinic Ligands to the Discovery of Σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.

Synthesis and Biological Evaluation of Novel Hybrids of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists.

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

Ligands for Brain Cholinergic Channel Receptors: Synthesis and in Vitro Characterization of Novel Isoxazoles and Isothiazoles As Bioisosteric Replacements for the Pyridine Ring in Nicotine

Affinity of Nicotinoids to a Model Nicotinic Acetylcholine Receptor (nAChR) Binding Pocket in the Human Brain

The optimization of a novel selective antagonist for human M<sub>2</sub> muscarinic acetylcholine receptor

Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy

An In Silico Method For Screening Nicotine Derivatives As Cytochrome P450 2a6 Selective Inhibitors Based On Kernel Partial Least Squares

Reversal of a Vigilance Decrement in the Aged Rat by Subtype-Selective Nicotinic Ligands

Novel Pyridyl Ring C5 Substituted Analogues Of 3-(1-Methyl-2(S)- Pyrrolidinylmethoxy)Pyridine (A-84543) As Highly Selective Agents For Neuronal Nicotinic Acetylcholine Receptor(Nachr)

Design and Synthesis of New Agents for Neuronal Nicotinic Acetylcholine Receptor (nachrs) Imaging.

Discovery of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists Containing an Isoxazolylpyridine Ether Scaffold That Demonstrate Antidepressant-like Activity. Part II

Molecular docking and dynamic simulation studies of α4β2 and α7 nicotinic acetylcholine receptors with tobacco smoke constituents nicotine, NNK and NNN

Pharmacokinetic and pharmacodynamic studies of nicotine in rat brain: a simultaneous investigation of nicotine metabolites and the release of neurotransmitters in vivo

Identification Of Novel Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor (Nachr) Agonists Based On An Isoxazole Ether Scaffold That Demonstrate Antidepressant-Like Activity

Prioritizing Genes Related to Nicotine Addiction Via a Multi-source-Based Approach